caa a22 4500 465735479 CHVBK 20180323111753.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00182083 doi (NATIONALLICENCE)springer-10.1007/BF00182083 Radioimmunoassay of glioma-associated antigen in cerebrospinal fluid and its usefulness for the diagnosis and monitoring of human glioma [Elektronische Daten] [Jun Yoshida, Ryohei Yamamoto, Toshihiko Wakabayashi, Masaaki Nagata, Hisao Seo] Summary: Quantitative determination of human glioma-associated antigen in cerebrospinal fluids (CSFs) obtained from 66 patients with a variety of neurological diseases was performed by solid-phase radioimmunoassay with a monoclonal antibody (G-22). In this system, the minimum detectable amount of the antigen in the CSF was 8 ng/ml. It was demonstrated that CSF diagnosis of glioblastoma might be possible in the case of small tumors with a diameter of less than 2 cm. CSFs obtained from all 18 patients with glioma were positive and the level varied from 11.2 to 186.1 ng/ml. The antigen level in the cystic fluid of the tumor was higher than that in CSF. There was a tendency for the antigen level in CSF to be correlated with the tumor size and the type of histology. The malignant types of glioblastoma or medulloblastoma showed higher levels than the benign type of ependymoma and astrocytoma. Most types of non-gliomatous brain tumor were negative except immature teratoma, meningioma with central neurofibromatosis, and metastatic brain tumor from lung cancer. We also noted that tumor progression or regression of malignant glioma could be predicted by the monitoring of the antigen in the CSF. Kluwer Academic Publishers, 1990 radioimmunoassay nationallicence glioma nationallicence brain tumor nationallicence tumor-associated antigen nationallicence cerebrospinal fluid nationallicence Yoshida Jun Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Yamamoto Ryohei Department of Research and Development, Amano Pharmaceutical Co., Aichi, Japan aut Wakabayashi Toshihiko Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Nagata Masaaki Central Laboratory, Koseiren Kamo Hospital, Toyota, Japan aut Seo Hisao Department of Endocrinology and Metabolism, Research Institute of Environmental Medicine, Nagoya, Japan aut Journal of Neuro-Oncology Kluwer Academic Publishers 8/1(1990-02-01), 23-31 0167-594X 8:1<23 1990 8 11060 https://doi.org/10.1007/BF00182083 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00182083 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yoshida Jun Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Yamamoto Ryohei Department of Research and Development, Amano Pharmaceutical Co., Aichi, Japan aut NATIONALLICENCE 700 1- Wakabayashi Toshihiko Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Nagata Masaaki Central Laboratory, Koseiren Kamo Hospital, Toyota, Japan aut NATIONALLICENCE 700 1- Seo Hisao Department of Endocrinology and Metabolism, Research Institute of Environmental Medicine, Nagoya, Japan aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 8/1(1990-02-01), 23-31 0167-594X 8:1<23 1990 8 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer